Neuron23

Neuron23 is an early-stage biotechnology company that develops precision medicine for neurological and immunological diseases. The company utilizes its AI-enabled drug and biomarker discovery platforms to accelerate the drug development process. 

As of March 2024, the company had five small molecule candidates in its pipeline, all of which were at the early stages of drug development. Its Parkinson's disease drug, which targets a protein called “leucine-rich repeat kinase 2,” (LRRK2) was in Phase 1 clinical trials. 

Key customers and partnerships

In September 2022 , Neuron23 partnered with QIAGEN to develop a next-generation companion diagnostic (CDx) for the Parkinson's disease drug, LRRK2. 

Funding and financials

Neuron23 was founded in 2018 through a partnership with Origenis, a biotechnology company based in Germany. In December 2020, the company emerged from stealth, raising a combined USD 113.5 million in Series A and B financing. 

In March 2022 , the firm raised USD 100 million in a Series C funding round led by SoftBank Vision Fund 2, with participation from existing investors WestLake Village BioPartners, Kleiner Parkins, and others. The funds were allocated for the development of its lead programs, its precision immunology platform, and research on its Parkinson’s drug candidate.